Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. ("Capstan"), a clinical-stage biotechnology company dedicated to advancing in vivo engineering of cells through RNA delivery using tLNPs, today ...

AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025. Management will participate in a fireside chat at 10:20 a.m. Central time.

AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside. Read why ABBV stock is a hold.

AbbVie shares rose Friday after the drugmaker's first-quarter results came in above analysts' expectations.

AbbVie (NYSE:ABBV) is scheduled to announce its earnings on Friday, April 25, 2025. Currently, the company holds a market capitalization of $307 billion. Over the past twelve months, AbbVie ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an analysis of ABBV stock now.

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the theft of trade secrets.

Partnership marks AbbVie's entrance into the obesity fieldAgreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global ...